|
Hyperinsulinemic hypoglycemia
|
0.120 |
Biomarker
|
disease |
HPO |
|
|
|
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study.
|
31496287 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lactate and MCTs, especially MCT1 and MCT4, are important contributors to tumor aggressiveness.
|
31395464 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1.
|
31564440 |
2020 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study.
|
31496287 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Conversely, we found that FoxO3 knockdown led to recovered migration/invasion abilities and increased pp65 and MCT-1/4 expression levels.
|
31729681 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that the oncogene Multiple Copies in T-cell Malignancy 1 (MCT-1/MCTS1) expression is a new poor-prognosis marker in patients with aggressive breast cancers.
|
30885232 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Luciferase assay and q-RT-PCR showed MCT1 is a direct target of miR-124 in both breast cancer cell lines and patient specimens.
|
31367191 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast-cancer cell glycometabolic coupling ring mediated by monocarboxylate transporter (MCT) 4 and MCT1 was then proved in the tumor microenvironment.
|
30698991 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review systematically summarizes the basic characteristics of MCT1 and its role in brain diseases and cancer, laying the foundation for further research on MCT1.
|
31631816 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that the oncogene Multiple Copies in T-cell Malignancy 1 (MCT-1/MCTS1) expression is a new poor-prognosis marker in patients with aggressive breast cancers.
|
30885232 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.
|
30617815 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The non-invasive imaging of these transporters in cancer patients via positron emission tomography (PET) is regarded to be valuable for the monitoring of therapeutic effects of MCT inhibitors.
|
31827199 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In tumor cells, MCT1 expression was associated with extended overall and progression-free survival and decreased nodal metastasis.
|
31404019 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCT1 expression was significantly increased in HPV-negative tumours, and inhibition suppressed tumour cell invasion, colony formation and promoted radiosensitivity.
|
30655616 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast-cancer cell glycometabolic coupling ring mediated by monocarboxylate transporter (MCT) 4 and MCT1 was then proved in the tumor microenvironment.
|
30698991 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As mammary tumor progression was promoted by oncogenic MCT-1 activation, tumor-promoting M2 macrophages were enriched in TME, whereas M2 macrophages were decreased and tumor-suppressive M1 macrophages were increased as the tumor was repressed via MCT-1 knockdown.
|
30885232 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo <sup>13</sup> C MRSI studies of orthotopic tumors in mice also showed a significant 52% decrease in hyperpolarized [1-<sup>13</sup> C]Lac/Pyr when comparing vorinostat-treated U87 GBM tumors with controls, and, as in the cell studies, this metabolic finding was associated with increased MCT1 and MCT4 expression in HDAC-inhibited tumors.
|
30561869 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumour development and progression.
|
31827199 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An xenograft mice model was established and evaluated for the in vivo tumor therapeutic effects of MCT1 inhibitor plus microRNA-124 treatments.
|
31367191 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumor development and progression.
|
31017677 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that expression of MCT1 in the NHL tumour compartment was significantly associated with a poor clinicopathological profile.
|
30790227 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Background</i>: Monocarboxylate transport protein 1 (MCT1) has been defined as a critical regulator in tumor energy metabolism, but bibliometric analysis of MCT1 research is rare.
|
30934693 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, silencing monocarboxylate transporter 1 (MCT1), the prominent path for lactate uptake in human tumor with siRNA significantly impaired organoid forming capacity of OSCC cells.
|
31209810 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene.
|
31605138 |
2019 |